GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
- PMID: 36356111
- DOI: 10.2337/dc22-1148
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Abstract
Objective: To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer.
Research design and methods: A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index.
Results: A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05).
Conclusions: In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.
© 2023 by the American Diabetes Association.
Comment in
-
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts.Diabetes Care. 2023 Feb 1;46(2):249-251. doi: 10.2337/dci22-0052. Diabetes Care. 2023. PMID: 36525594 Free PMC article. No abstract available.
-
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.Diabetes Care. 2023 May 1;46(5):e117. doi: 10.2337/dc22-2300. Diabetes Care. 2023. PMID: 37185678 No abstract available.
-
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.Diabetes Care. 2023 May 1;46(5):e118. doi: 10.2337/dc22-2454. Diabetes Care. 2023. PMID: 37185687 No abstract available.
-
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.Diabetes Care. 2023 May 1;46(5):e120. doi: 10.2337/dc23-0134. Diabetes Care. 2023. PMID: 37185688 No abstract available.
-
Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.Diabetes Care. 2023 May 1;46(5):e121-e122. doi: 10.2337/dci23-0016. Diabetes Care. 2023. PMID: 37185689 No abstract available.
-
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.Diabetes Care. 2023 May 1;46(5):e119. doi: 10.2337/dc23-0076. Diabetes Care. 2023. PMID: 37185691 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical